Bristol-Myers Squibb Company (BMY)

Net profit margin

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	US$ in thousands	-8,948,000	8,025,000	6,327,000	6,994,000	-9,015,000
Revenue	US$ in thousands	48,300,000	45,006,000	46,159,000	46,385,000	42,518,000
Net profit margin		-18.53%	17.83%	13.71%	15.08%	-21.20%

December 31, 2024 calculation

Net profit margin = Net income ÷ Revenue
= $-8,948,000K ÷ $48,300,000K
= -18.53%

Net profit margin is a crucial financial ratio that indicates the percentage of revenue that translates into profit for a company after all expenses are deducted. Analyzing Bristol-Myers Squibb Company's net profit margin over the years reveals fluctuations in its profitability.

In 2020, the net profit margin was -21.20%, indicating that the company incurred a loss, potentially due to high expenses relative to revenue. However, by the end of 2021, the net profit margin improved significantly to 15.08%, showcasing a strong turnaround and efficient cost management.

In 2022 and 2023, the net profit margin remained relatively stable at 13.71% and 17.83%, respectively, indicating consistent profitability levels. This stability suggests effective operational strategies and financial management during these periods.

However, by the end of 2024, the net profit margin saw a decline to -18.53%, indicating a significant decrease in profitability. This decline could be attributed to various factors such as increased expenses, declining revenues, or one-time charges impacting the bottom line.

Overall, Bristol-Myers Squibb Company's net profit margin demonstrates varying levels of profitability over the analyzed period, reflecting the company's ability to navigate changing market conditions and operational challenges. Monitoring and understanding these fluctuations are essential for investors and stakeholders to assess the company's financial health and performance accurately.